Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Preoperative Botensilimab with or without Balstilimab for Patients with Resectable, Locally Advanced pMMR or dMMR Colon Cancer: the UNICORN Trial by GONO

November 2, 2026

,

Ghelardi, F. et al.

Nature Medicine

Phase II Trial

Colorectal (CRC)

View Publication

Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200

Our Science

Pipeline

Publications

Clinical Trials

Immunotherapy

About BOT + BAL

Company

Our History

Our Team

Careers

Partners

Access

Patient Access

Contact Medical Affairs

Resources

Press Releases

In the News

Patient Resources

FAQs

Investors

Investor Overview

Events

Financial Information

Opt-out preferences Cookie Policy Terms and Conditions of Use Privacy Policy Community Guidelines Access to Investigational Medicines Policy Report Adverse Event Investor Portal

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Publishing the Frontiers of Immuno-Oncology

Preoperative Botensilimab with or without Balstilimab for Patients with Resectable, Locally Advanced pMMR or dMMR Colon Cancer: the UNICORN Trial by GONO

Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Fc-Enhanced Anti-CTLA-4 Antibody, Botensilimab, Enhances the Efficacy of Multiple Therapeutic Modalities in Immunotherapy-Refractory Tumor Models

Preclinical Dose-Pharmacokinetic-Efficacy Modeling of Botensilimab Using a Mouse Surrogate of the Fc-Enhanced Anti-CTLA-4 Antibody

AGEN1721, a First-in-Class FC-Enhanced Bifunctional Antibody Targeting FAP and TGFB, Remodels the Tumor Microenvironment to Overcome Cancer-Associated Fibroblast-Mediated Immune Suppression